title: Intermittent calcitriol therapy in secondary hyperparathyroidism: a comparison between oral and intraperitoneal administration.
abstract: BACKGROUND
  Intermittent oral or intravenous doses of calcitriol given two or three times per week are commonly used to treat secondary hyperparathyroidism (secondary HPT). This study was undertaken to compare the biochemical and skeletal responses to thrice weekly intraperitoneal (i.p.) versus oral doses of calcitriol in children with secondary HPT undergoing peritoneal dialysis (CCPD).
  
  
  METHODS
  Forty-six patients aged 12.5+/-4.8 years on CCPD for 22+/-25 months were randomly assigned to treatment with oral (p.o.) or i.p. calcitriol for 12 months; 17 subjects given p.o. calcitriol and 16 subjects given i.p. calcitriol completed the study. Bone biopsies were performed at the beginning and at the end of the study, while determinations of serum and total ionized calcium, phosphorus, alkaline phosphatase, parathyroid hormone (PTH) and calcitriol levels were done monthly.
  
  
  RESULTS
  Serum total and ionized calcium levels were higher in subjects treated with i.p. calcitriol, P < 0.0001, whereas serum phosphorus levels were higher in those given p.o. calcitriol, P < 0.0001. For the i.p. group, serum PTH levels decreased from pre-treatment values of 648+/-125 pg/ml to a nadir of 169+/-57 pg/ml after nine months. In contrast, serum PTH levels did not change from baseline values of 670+/-97 pg/ml in subjects given p.o. calcitriol, P < 0.0001 by multiple regression analysis. Serum alkaline phosphatase levels were also lower in patients treated with i.p. calcitriol, P < 0.0001, but there was no difference between groups in the average dose of calcitriol given thrice weekly. The skeletal lesions of secondary HPT improved in both groups, 33% of patients developed adynamic bone lesion.
  
  
  CONCLUSIONS
  Differences in the bioavailability of calcitriol and/or in phosphorus metabolism may account for the divergent biochemical response to p.o. and i.p. calcitriol.
authors.affiliation: Department of Pediatrics, UCLA School of Medicine, Los Angeles, California, USA. salusky@crc.medsch.ucla.edu
authors.forename: I B
authors.initials: IB
authors.lastname: Salusky
authors.forename: B D
authors.initials: BD
authors.lastname: Kuizon
authors.forename: T R
authors.initials: TR
authors.lastname: Belin
authors.forename: J A
authors.initials: JA
authors.lastname: Ramirez
authors.forename: B
authors.initials: B
authors.lastname: Gales
authors.forename: G V
authors.initials: GV
authors.lastname: Segre
authors.forename: W G
authors.initials: WG
authors.lastname: Goodman
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D001842:Bone and Bones / Q000473:pathology; D002117:Calcitriol / Q000008:administration & dosage*; D002118:Calcium / Q000097:blood; D002648:Child; D005260:Female; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D007274:Injections, Intraperitoneal; D008297:Male; D010758:Phosphorus / Q000097:blood; D011446:Prospective Studies
chemical_list: D010758:Phosphorus; D002117:Calcitriol; D002118:Calcium